Blog
40 Articles
GENERATE Trial Expands Eligibility
Dr. Sapna Syngal explains the expanded eligibility standards for the GENERATE Study for genetic testing of pancreatic cancer patients and relatives.
COMBATing Pancreatic Cancer
Dr. Manuel Hidalgo explains the COMBAT trial, which combines immunotherapy, a checkpoint inhibitor, and chemotherapy to attack pancreatic cancer.
A PARP Inhibitor Approval for Pancreatic Cancer
PARP inhibitors, a type of targeted therapy, are being studied as treatment for pancreatic cancer in a number of clinical trials.
Finding a Safe Dose of a New Drug for Some Types of Solid Tumors
LMB-100 is a lab-created protein that targets mesothelin. It is being tested against pancreatic cancer and other solid tumors in a clinical trial.
Tough Tortoise of a Drug Beating Metastatic Pancreatic Cancer
Rexahn Pharmaceuticals is testing RX-3117, a slow-releasing drug similar to gemcitabine, in a clinical trial for metastatic pancreatic cancer patients.
A Combination of Neoadjuvant Chemotherapy and Radiation Shows Promise
Dr. Alok Khorana discusses the results of clinical trials of neoadjuvant chemotherapy and radiation to make surgery more effective.
Targeting Cancer Metabolism
Researchers from Tyme Technologies are focusing on cancer cell metabolism, particularly tyrosine, as a way to kill cancer cells.
Making Surgery An Option for More Pancreatic Cancer Patients
Dr. John Chabot explains that more pancreatic cancer patients may qualify for surgery if they consult an experience pancreatic surgical team.
Immunotherapy Treatments Provide Hope to Pancreatic Cancer Patients
Dr. Robert Vonderheide of the Abramson Cancer Center at the University of Pennsylvania describes immunotherapy trials for pancreatic cancer.
New Drug Shows Positive Results in Early Trials
A new drug called PEGPH20, which helps chemotherapy drugs reach their target, is showing positive results in an ongoing pancreatic cancer trial.